So without any further ado, Belinda, I believe you're going to start us off.

Thank you, everybody.

It's our great pleasure to present for you the Australasian resuscitation and sepsis evaluation, fluids or vasopressors in emergency department sepsis, the ARISE fluids trial.

This is an investigator-initiated study, and we have no conflicts of interest to declare.

The ARISE Fluids trial is a phase three prospective, open-label, of course, multi-centre randomised control trial.

The population of interest were 1,000 adults, patients presenting to the ED with early septic shock.

The intervention arm, known as the vasopressor group, is restricted IV fluids and early vasopressors for up to 24 hours.

So whilst, yes, it was reported, I'm not too sure how clinically important it was.